At a glance
- Originator University of North Carolina at Chapel Hill; Wake Forest University Health Sciences
- Class Antineoplastics; Deoxyribonucleosides; Phospholipids; Pyrimidine nucleosides; Small molecules
- Mechanism of Action DNA synthesis inhibitors; Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)
- 28 May 2021 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in USA (PO)
- 31 Dec 2020 Aikido Pharma has patent protection for KPC 34 in USA